Back to Search Start Over

DBP rs7041 and DHCR7 rs3829251 are Linked to CD4 + Recovery in HIV Patients on Antiretroviral Therapy.

Authors :
Resino S
Jiménez-Sousa MÁ
Blanco J
Pacheco YM
Del Romero J
Peraire J
Virseda-Berdices A
Muñoz-Gómez MJ
Galera-Peñaranda C
García-Fraile LJ
Benito JM
Rallón N
Source :
Frontiers in pharmacology [Front Pharmacol] 2022 Jan 18; Vol. 12, pp. 773848. Date of Electronic Publication: 2022 Jan 18 (Print Publication: 2021).
Publication Year :
2022

Abstract

Background: The lack of the recovery of CD4 <superscript>+</superscript> T-cells (CD4 <superscript>+</superscript> recovery) among immunodeficiency virus (HIV)-infected patients on antiretroviral therapy (ART) is not well known. We aimed to analyze the association between single nucleotide polymorphisms (SNPs) underlying vitamin D metabolism and the CD4 <superscript>+</superscript> recovery in naïve HIV-infected patients who started ART with low baseline CD4 <superscript>+</superscript> . Methods: We conducted a retrospective study in 411 naïve individuals with plasma HIV load >200 copies/mL and CD4 <superscript>+</superscript> <200 cells/mm <superscript>3</superscript> . During 24 months of follow-up, all patients had plasma HIV load <50 copies/mL. DNA genotyping was performed using the Sequenom MassARRAY platform. The outcome variable was the change in CD4 <superscript>+</superscript> during the study. Results: CD4 <superscript>+</superscript> recovery was higher in patients carrying DBP rs7041 AA genotype (AA versus CC/AC) and DHCR7 rs3829251 AA genotype (AA versus GG/AG) ( p -value < 0.05). DBP rs7041 AA genotype was linked to increase in CD4 <superscript>+</superscript> (adjusted arithmetic mean ratio (aAMR) = 1.22; q -value = 0.011), increase in CD4 <superscript>+</superscript> ≥P75th [adjusted odds ratio (aOR) = 2.31; q -value = 0.005], slope of CD4 <superscript>+</superscript> recovery (aAMR = 1.25; q -value = 0.008), slope of CD4 <superscript>+</superscript> recovery ≥ P75th (aOR = 2.55; q -value = 0.005) and achievement of CD4 <superscript>+</superscript> ≥500 cells/mm <superscript>3</superscript> (aOR = 1.89; q -value = 0.023). Besides, DHCR7 rs3829251 AA genotype was related to increase in CD4 <superscript>+</superscript> (aAMR = 1.43; q -value = 0.031), increase in CD4 <superscript>+</superscript> ≥P75th (aOR = 3.92; q -value = 0.030), slope of CD4 <superscript>+</superscript> recovery (aAMR = 1.40; q -value = 0.036), slope of CD4 <superscript>+</superscript> recovery ≥ P75th (aOR = 3.42; q -value = 0.031) and achievement of CD4 <superscript>+</superscript> ≥500 cells/mm <superscript>3</superscript> (aOR = 5.68; q -value = 0.015). Conclusion: In summary, DHCR7 rs3829251 and DBP rs7041 polymorphisms were associated with CD4 <superscript>+</superscript> recovery in HIV-infected patients who started cART with low CD4 <superscript>+</superscript> T-cell counts.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Resino, Jiménez-Sousa, Blanco, Pacheco, del Romero, Peraire, Virseda-Berdices, Muñoz-Gómez, Galera-Peñaranda, García-Fraile, Benito and Rallón.)

Details

Language :
English
ISSN :
1663-9812
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in pharmacology
Publication Type :
Academic Journal
Accession number :
35115928
Full Text :
https://doi.org/10.3389/fphar.2021.773848